Skip to main content

Noyes Timothy P's Form 4 filing

Jade Biosciences, Inc. (JBIO) · filed Mar 3, 2023

Accession no.
0001415889-23-004192
Filed
Mar 3, 2023
Trade date
Mar 1, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $357.2K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Noyes Timothy PCIK 0001185035Director, Officer (CHIEF EXECUTIVE OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 1, 2023Common StockMOption exerciseAcquired+15,000$2.14+$32,10015,000Direct
Mar 1, 2023Common StockSSaleDisposed−5,962$22.71F2−$135,397.029,038Direct
Mar 1, 2023Common StockSSaleDisposed−2,672$23.81F3−$63,620.326,366Direct
Mar 1, 2023Common StockSSaleDisposed−5,316$24.69F4−$131,252.041,050Direct
Mar 1, 2023Common StockSSaleDisposed−1,050$25.67−$26,953.50Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 1, 2023Common StockMOption exerciseDisposed−15,000$0.00$0433,381Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.25 to $23.24, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.31 to $24.20, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.33 to $25.06, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)